NCT00865423View on ClinicalTrials.gov

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 28, 2001

Study Completion Date

March 31, 2001

Conditions
Healthy
Interventions
DRUG

Gabapentin 800 mg Tablets, single dose

A: Experimental Subjects received Purepac formulated products under fasting conditions

DRUG

NEURONTIN® 800 mg Tablets, single dose

B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865423 - A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions | Biotech Hunter | Biotech Hunter